文献速递鼻科

皮质类固醇缓释鼻窦支架相关不良事件:MAUDE数据库分析

Adverse Events Associated With Corticosteroid-Eluting Sinus Stents: A MAUDE Database Analysis.
PubMed 文献 · Otolaryngol Head Neck Surg · 2021-04-13

本研究基于美国FDA的MAUDE数据库(2011-2020年)回顾性分析皮质类固醇缓释支架(CES)的不良事件报告,共纳入28例事件,全部与Propel系列支架相关,Sinuva支架无报告。最常见不良事件为术后感染(39%,n=11),其中4例眶周蜂窝织炎、5例真菌感染;其次为支架移位(21%,n=6)。29%(8例)患者需再次手术取出支架。

要点

  • CES相关不良事件以术后感染最常见,需警惕真菌感染和眶周蜂窝织炎。
  • 支架移位是第二常见不良事件,部分患者需再次手术取出。
  • 术前知情同意应告知患者感染、移位及再手术风险。

核心结论

  • CES最常报告的不良事件为术后感染(包括多例真菌感染),其次为支架移位。
  • 提高对CES并发症的认识有助于患者知情同意和外科决策。

研究设计与样本

  • 回顾性横断面研究,查询美国FDA的MAUDE数据库(2011-2020年)中CES相关不良事件报告。
  • 纳入FDA批准的CES包括Propel、Propel Mini、Propel Contour和Sinuva(Intersect ENT)。

主要发现

  • 共报告28例不良事件,全部与Propel系列支架相关,Sinuva支架无相关报告。
  • 22例为患者相关不良事件,6例为器械相关事件。
  • 最常见不良事件为术后感染,占39%(n=11),其中4例发生眶周蜂窝织炎,5例发生真菌感染。
  • 第二常见不良事件为支架移位,占21%(n=6)。
  • 29%(8例)患者需再次手术室干预并取出CES。

临床怎么用

  • 临床使用CES时应警惕术后感染(尤其真菌感染和眶周蜂窝织炎)及支架移位风险。
  • 术前知情同意应告知患者CES相关不良事件及可能的再手术取出风险。
  • 外科决策时可参考上述不良事件谱权衡CES的获益与风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Corticosteroid-eluting stents (CESs) are increasingly used after endoscopic sinus surgery to reduce the need for revision surgery, but their use is not without risks. The objective of this study is to describe adverse events related to CESs. STUDY DESIGN: Retrospective cross-sectional study. SETTING: The US Food and Drug Administration's MAUDE database (2011-2020; Manufacturer and User Facility Device Experience). METHODS: The MAUDE database was queried for reports of adverse events involving the use of CESs approved by the Food and Drug Administration, including Propel, Propel Mini, Propel Contour, and Sinuva (Intersect ENT). RESULTS: There were 28 reported adverse events in total, with all events being related to the Propel family of stents and none related to Sinuva stents. Overall, 22 were categorized as patient-related adverse events and 6 as device-related events. The most common adverse event was related to postoperative infection, accounting for 39% (n = 11) of all complications. Four of these patients developed periorbital cellulitis, and 5 developed a fungal infection. The second-most common adverse event was migration of the stent, representing 21% of all complications (n = 6). Overall, 8 patients (29%) in our cohort required reintervention in the operating room, with subsequent removal of the CES. CONCLUSION: The most commonly reported adverse events were postoperative infection, including multiple cases of fungal infection, followed by migration of the stent. An increased awareness of the complications associated with CESs can be used to better inform patients during the consenting process as well as surgeons in their surgical decision making.

来源:Otolaryngol Head Neck Surg,查看原文。版权归原作者所有。

引用

  1. Narwani V, Torabi SJ, Kasle DA, et al. Adverse Events Associated With Corticosteroid-Eluting Sinus Stents: A MAUDE Database Analysis. Otolaryngol Head Neck Surg. 2021. PMID: 33848437. doi:10.1177/01945998211006930

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。